(Q37872240)

24 August 2017

1 reference

title

Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy (English)

1 reference

24 August 2017

1 reference

D R Yates

1

1 reference

PubMed ID

21544661

24 August 2017

M Rouprêt

series ordinal

2

1 reference

PubMed ID

21544661

24 August 2017

language of work or name

1 reference

5 May 2011

1 reference

24 August 2017

World Journal of Urology

1 reference

24 August 2017

29

1 reference

24 August 2017

415-422

1 reference

24 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s00345-011-0681-4

24 August 2017

0 references

cites work

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Optimal management of high-risk T1G3 bladder cancer: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Definition and management of patients with bladder cancer who fail BCG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Combination of BCG and interferon intravesical immunotherapy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Pharmacokinetic study to optimize the intravesical administration of gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 t

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

New therapies for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0681-4

Defining bacillus Calmette-Guerin refractory superficial bladder tumors

21 January 2018

1 reference

12 December 2020

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy

1 reference

12 December 2020

Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer

1 reference

12 December 2020

Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy

1 reference

12 December 2020

5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group

1 reference

12 December 2020

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

1 reference

12 December 2020

Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model

1 reference

12 December 2020

Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?

1 reference

12 December 2020

Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study

1 reference

12 December 2020

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer

1 reference

12 December 2020

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

1 reference

12 December 2020

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

12 December 2020

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

1 reference

12 December 2020

Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORT

1 reference

12 December 2020

A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer

1 reference

12 December 2020

Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

1 reference

12 December 2020

Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy

1 reference

12 December 2020

Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer

1 reference

12 December 2020

10.1007/S00345-011-0681-4

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21544661